Is patient eligible for Xolair? These questions will help you find out However, BlueCross BlueShield of Tennessee formulated a tool that will help you make the medical- necessity decision. To determine the eligibility status of patients who might receive Xolair, follow this Pharmaceutical Decision Support Tree: 1. Has the individual been diagnosed with an allergic condition, other than allergy-related asthma? If yes, this does not meet medical-necessity and/or medical-appropriateness criteria. If no, go to question #2. 2. Does the individual have a diagnosis of moderate to severe persistent allergic asthma? If yes, go to question #3. If no, this does not meet medical-necessity and/or medical-appropriateness criteria. 3. Is the individual 12 years of age or older? If yes, go to question #4. If no, this does not meet medical-necessity and/or medical-appropriateness criteria. 4. Did the individual test positive to at least one perennial aeroallergen by a skin test (for instance, prick/puncture test, intracutaneous test) or a blood test (such as RAST)? If yes, go to question #5. If no, this does not meet medical-necessity and/or medical-appropriateness criteria. 5. Is the individual's IgE level greater than or equal to 30 and less than or equal to 700 IU/mL? If yes, go to question #6. If no, this does not meet medical-necessity and/or medical-appropriateness criteria. 6. Is the individual currently using oral/inhaled corticosteroids at maximum doses? If yes, go to question #7. If no, this does not meet medical-necessity and/or medical-appropriateness criteria. 7. Is the individual's asthma inadequately controlled despite the regular use of inhaled corticosteroids at maximum doses? If yes, go to question #8. If no, this does not meet medical-necessity and/or medical-appropriateness criteria. 8. Is the individual being treated with a long-acting beta 2-agonist? If yes, this satisfies medical-necessity and medical- appropriateness criteria If no, this does not meet medical-necessity and/or medical-appropriateness criteria.